The removal of the mutant DMPK mRNA from the patients’ tissues using AONs and siRNAs was developed by several groups as one of the logical therapeutic approaches to treat DM1 (Figure 2B). This evidence concerns the gene DMPK and myotonic dystrophy type 1.